Dear Doctor,
Don’t let their hearts fail
Promise to secure them
00:07
Dear Doctor,
Introducing, In HFrEF
SACUHART, the brand of Sacubitril+Valsartan
available in 50/100 mg Tablets.
Doctor, promise to secure the failing heart
Doctor, SACUHART is recommended in HFrEF as a
replacement for ACEi/ARB
1.Improves breathlessness
2.Reduces the risk of hHF
3.Improves Survival
00:35
Dear Doctor,
Neprilysin & RAAS both are elevated in HF & are
predictive of CV death and hHF
Sacubitrilat, the active form of Sacubitril, inhibits
Neprilysin and enhances Vasorelaxation.
Valsartan blocks binding of Angiotensinogen II to
AT1 receptor and inhibits vasoconstrictions.
Also Guidelines
(ACC/AHA/HFSA 2022 & ESC 2021) recommend
ARNI as the first line of treatment in HFrEF
instead of ACEi
01:15
Dear Doctor,
Support their spirit to live
As SACUHART improves HF parameters
Decreases NT-ProBNP upto 73% in De Novo HF
patients & upto 40% in ACEi treated patients
Increases LVEF upto 14%
Improves NYHA class by decreasing the
proportion of NYHA Class III-IV patients
from 44.6%-24%